OSI-461 (OSI).

OSI Pharmaceuticals is developing OSI-461, a potent analog of exisulind, for the potential treatment of cancer and inflammatory bowel disease. In August 2001, OSI-461 entered phase II trials involving patients with chronic lymphocytic leukemia. In July 2002, the company embarked on a pilot phase II study evaluating OSI-461 for the treatment of Crohn's disease. By October 2002, Cell Pathways had selected hormone-refractory prostate cancer as the lead cancer indication for clinical development of OSI-461.